Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

M. S. Aapro, F. H. van Wijk, G. Bolis, B. Chevallier, M. E L van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. NooijM. Presti, C. Scarabelli, T. A W Splinter, E. Ploch, L. V A Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P. G. Harper, C. Madronal, M. Namer, G. Scarfone, J. E G M Stoot, I. Teodorovic, C. Coens, I. Vergote, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m2 alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36% versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P

Original languageEnglish
Pages (from-to)441-448
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 1 2003

Keywords

  • Chemotherapy
  • Cisplatin
  • Doxorubin
  • Endometrial carcinoma
  • Phase III
  • Randomised clinical trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group'. Together they form a unique fingerprint.

Cite this